Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc (NASDAQ: NCNA) is a clinical-stage biopharmaceutical company focused on developing ProTide-based cancer therapies, and the NCNA news feed highlights the company’s ongoing clinical, regulatory, and corporate developments. NuCana reports that it is applying its proprietary ProTide technology to transform widely used nucleoside analog chemotherapy agents into new medicines designed to overcome key limitations of these drugs and generate higher concentrations of active anti-cancer metabolites in cancer cells.
News about NuCana frequently centers on its two lead product candidates, NUC-7738 and NUC-3373. Coverage includes updates from the NuTide:701 Phase 1/2 study of NUC-7738 in advanced solid tumors and in combination with pembrolizumab in patients with melanoma, including PD-1 inhibitor-resistant metastatic melanoma. Articles also report on data from the NuTide:303 Phase 1b/2 study of NUC-3373 in combination with pembrolizumab for advanced solid tumors and with docetaxel for lung cancer, as well as preclinical findings that explore immunogenic effects and synergy with PD-1 inhibitors.
Investors following NCNA news can expect announcements on clinical data presented at major oncology meetings, such as European Society for Medical Oncology congresses, publications in scientific journals and preprint servers, and updates on intellectual property, including composition-of-matter patents for NUC-7738. The news flow also covers financial results, capital-raising activities such as at-the-market offerings and warrant transactions, Nasdaq listing and ADS ratio changes, and leadership or board changes reported in Form 6-K filings.
This page aggregates these company-issued press releases and related disclosures so readers can monitor NuCana’s progress in oncology drug development, track milestones for NUC-7738 and NUC-3373, and review structural updates that may affect the NCNA stock listing and capital structure.
NuCana plc (NASDAQ: NCNA) reported promising findings from presentations at the AACR Annual Meeting 2021. The data highlights the efficacy of NUC-3373 in advanced colorectal cancer, showing a 62% disease control rate among 38 patients, with no severe toxicities. NUC-7738 demonstrated anti-cancer activity in advanced solid tumors and high levels of the active metabolite 3’-dATP. Additionally, Acelarin showed persistent DNA damage in biliary tract cancer cells. These advances showcase NuCana's innovative ProTide technology aimed at enhancing cancer treatment outcomes.
NuCana plc (NASDAQ: NCNA) reported its financial results for Q4 and the year ended December 31, 2020, showing a net loss of £30.7 million, up from £21.4 million in 2019. Cash reserves declined to £87.4 million from £100.7 million in Q3 2020. The company raised $80 million in a follow-on offering to strengthen its balance sheet. Encouraging clinical data for NUC-3373 and NUC-7738 were highlighted, along with continued enrollment in the Phase III biliary tract cancer study (NuTide:121). New board appointments were also announced, aiming to enhance strategic direction.
NuCana plc (Nasdaq: NCNA) announced participation in several upcoming healthcare conferences. Hugh Griffith (CEO) and Don Munoz (CFO) will present at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 1:30 PM ET, and at the Oppenheimer's 31st Annual Healthcare Conference on March 18, 2021, at 9:20 AM ET. The presentations will be webcast live and available for replay on the company's website. NuCana focuses on developing enhanced cancer therapies using its proprietary ProTide technology, aiming to improve outcomes for patients with various types of cancer.
NuCana (NASDAQ: NCNA) reported interim data from its NuTide:302 study at the ASCO GI Conference, revealing a promising 62% disease control rate and notable tumor shrinkage in heavily pre-treated metastatic colorectal cancer patients. The study evaluated NUC-3373, a thymidylate synthase inhibitor, for safety and efficacy. The drug exhibited a favorable safety profile, with no severe side effects compared to traditional therapies like 5-FU. Clinical data highlighted individual cases showing significant tumor reductions, suggesting NUC-3373's potential as a new backbone treatment.
NuCana announced the appointment of Andrew Kay as the new Chairman of its Board of Directors. Kay, a seasoned executive with over 30 years in the biotechnology sector, has previously held leadership roles at various successful companies, including Algeta, Wilson Therapeutics, and KaNDy Therapeutics. His experience includes pivotal drug development and commercialization successes. This leadership transition is expected to enhance NuCana's strategic direction and accelerate the advancement of its ProTide pipeline, which focuses on improving cancer treatment outcomes.
NuCana plc (NASDAQ: NCNA) reported promising final results from its Phase Ib study of Acelarin combined with cisplatin for advanced biliary tract cancer (ABC-08), showcasing a high Objective Response Rate of 44% compared to 26% in the standard treatment group. The treatment demonstrated a favorable safety profile, with responses across all cancer sub-types. The ongoing Phase III NuTide:121 study aims to recruit up to 828 patients, with potential for accelerated approval based on early efficacy data. The company is committed to enhancing treatment options for this challenging disease.
NuCana plc (NASDAQ: NCNA) reported a successful $80 million public offering and shared third-quarter 2020 financial results. As of September 30, 2020, cash and equivalents reached £100.7 million, up from £47.8 million in June 2020. The company posted a net loss of £8.4 million, compared to £3.9 million in Q3 2019. NuCana highlighted promising interim data for NUC-3373 and NUC-7738 presented at ESMO Virtual Congress 2020, with expectations for upcoming milestones, including new drug applications and clinical trial updates in 2021.
NuCana plc (NASDAQ: NCNA) announced that Hugh Griffith, CEO, and Don Munoz, CFO, will present at the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. A pre-recorded presentation will be available for replay starting November 23, 2020. NuCana focuses on enhancing cancer treatment through its ProTide technology, developing innovative medicines like Acelarin and NUC-3373, derived from standard chemotherapy agents. These candidates aim to overcome cancer resistance mechanisms, with several in various phases of clinical trials.
NuCana plc (NASDAQ: NCNA) announced its participation in the Jefferies Virtual London Healthcare Conference. CEO Hugh Griffith and CFO Don Munoz will present on November 18, 2020, at 11:45 AM GMT, with a live webcast available for replay on their website.
NuCana is focused on developing improved cancer therapies using its ProTide technology. Their pipeline includes ProTides Acelarin, NUC-3373, and NUC-7738, targeting various cancers to overcome resistance mechanisms and enhance efficacy.
NuCana plc appoints Bali Muralidhar, M.D., Ph.D. to its Board of Directors, enhancing its leadership team as it advances its ProTide pipeline targeting cancer treatment. This follows a successful $80 million public offering, with significant investment from Abingworth, a prominent life sciences investment firm. The new funding is expected to accelerate the development of ProTides, which include three products currently in clinical trials. Management believes these advancements could significantly improve patient outcomes in oncology.
FAQ
What is the current stock price of Nucana (NCNA)?
What is the market cap of Nucana (NCNA)?
